



**Allergy and Asthma
Adam Williams, MD**

July 2, 2026

Dear Oregon Prescription Drug Affordability Board Members:

I am writing as a clinician on behalf of the hundreds of my patients who benefit from Omalizumab (Xolair) for the treatment of their debilitating conditions. In case you are not aware, Xolair is FDA approved for the management of severe allergic asthma, chronic rhinosinusitis with nasal polyposis, chronic spontaneous urticaria, and prevention of anaphylaxis from food allergies. With over 20 years of use for these indications in thousands of Oregonians with these conditions, the impact this drug has had is immeasurable. "Affordability" determinations are likely limited in their ability to measure the positive impact of a medication for the lives of those affected.

These conditions are debilitating and have limited alternative treatment options. Food allergy in particular is a devastating condition to have. I have seen first hand the changes in the quality of life of those affected by food allergy when treated with Xolair. It is quite impressive. Similarly, for chronic spontaneous urticaria and allergic asthma, the words "it has been life changing" are often heard in relation to the relief patients get from treatment with Xolair.

All allergists turn to products like Xolair ONLY when more affordable options (of equal or better safety) have been exhausted. For many of these conditions, medications are either not available or are severely limited, making Xolair the only option.

I ask that the Board be mindful of these facts when reviewing this medication.

Thank you.

Adam Williams, MD, FAAAAI